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ABSTRACT 
This article refers to simple isocratic reverse-phase high-performance liquid chromatographic method (RP-HPLC) developed for the 
simultaneous quantification of Escitalopram Oxalate (EST) and Clonazepam (CZP) in active pharmaceutical ingredient and pharmaceuticals. The 
separation of the two drugs was attained using a C₁₈ column (250mm×4.6mm, 5µ) as a stationary phase. The mobile phase was used as a mixture 
of methanol; acetonitrile; and 0.05M potassium dihydrogen orthophosphate buffer (pH 4 adjusted by orthophosphoric acid) with an isocratic 
ratio of 40:20:40 v/v. Detection was made by using PDA detector at 210 nm. Escitalopram Oxalate (RT= 4.428 minutes) and Clonazepam (RT= 
6.532 minutes) were separated in a single chromatographic run with resolution of 8.719. The calibration plot indicated good linear relationship 
with r2 = 0.998 for Escitalopram Oxalate in concentration range of 32 µg/ml - 48 µg/ml and r2 = 0.999 for Clonazepam in concentration range of 
16 µg/ml - 24 µg/ml. The retrievals for Escitalopram Oxalate and Clonazepam were found to be 99.75% and 99.00%, respectively. The 
established analytical method was validated and found acceptable as per ICH guidelines for linearity, precision, accuracy, specificity, limit of 
detection, limit of quantification, robustness and stability. Escitalopram Oxalate and Clonazepam individually as well as in combination were 
exposed to different stress conditions like acid, base, thermal, photolytic and oxidation degradation and peaks of a degraded product were well 
determined from peaks of pure drug. This method is modest, quick and appropriate for routine quality control analysis. 
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INTRODUCTION 
Escitalopram oxalate (EST) (Figure 1a) is chemically known 
as S-(+)-1-[3-(dimethyl-amino) propyl]-1-(p-fluro-phenyl)- 
5-phthalancarbonitrile oxalate, which fits to the class of 
compounds known as antidepressant and is the S-
enantiomer of racemic citalopram1. Escitalopram is 
spontaneously soluble in dimethlysulfoxide (DMSO), 
methanol and, sparingly soluble in ethanol and water. 
Escitalopram is insoluble in heptane but slightly soluble in 
ethyl acetate. 
Escitalopram oxalate originates in category of oral selective 
serotonin reuptake inhibitor (SSRI) and proved highly potent 
with in vitro and in vivo studies. Escitalopram mainly used 
for the management of generalized Anxiety Disorder and 
major depressive disorder. Escitalopram works by specific 
competitive inhibition of the membrane transporter of 
serotonin2. As per studies Escitalopram discovered to be 
more than twice as potent as citalopram and is the highly 
selective drug in its class2-3.Several analytical methods have 
been developed for the estimation of escitalopram oxalate in 
pharmaceutical formulations and/or biological fluids include 
liquid chromatography coupled with mass spectrometry4. 
     
(a)                                                                              (b) 
Figure 1: Chemical Structures of (a) EST  (b) CZP 
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Clonazepam (CZP) (Figure 1b) is a derivative of 
benzodiazepine related to diazepam, with distinct 
antiepileptic properties5. It is official in BP6 and USP7. 
Chemically clonazepam is 5-(2-chlorophenyl)-1, 3-dihydro-
7-nitro-2H-1,4-benzodiazepine-2-one. Clonazepam is a light 
yellow crystalline powder that is practically odorless. It is 
freely very soluble in acetone, ethanol and methanol and 
insoluble in water. 
Clonazepam is known as commercial drug to treat the 
depression associated with anxiety and highly used for the 
treatment of seizure and anxiety disorders. It works by 
Allosteric interactions between gamma-aminobutyric acid 
(GABA) receptors and central benzodiazepine receptors and 
potentiate the effects of GABA. GABA being an inhibitory 
neurotransmitter, helps to increase inhibition of the 
ascending reticular activating system (RAS)8. 
The literature survey reveals the accessibility of analytical 
methods for the quantitative estimation of Escitalopram 
Oxalate (EST) and Clonazepam (CZP) individually, or 
combination of these drugs with other drugs typically using 
chromatographic methods with different detectors such as 
electrochemical9 or mass spectrometry detection10-12 
fluorescence13, gas chromatography with electron-capture14 
or mass spectrometry15 detection. The present study 
describes the development and validation of a stability 
indicating RP-HPLC method for the simultaneous estimation 
of EST and CZP in active pharmaceutical ingredient and 
marketed tablet formulation. The developed method was 
effectively applied for the routine analysis of EST and CZP in 
bulk and marketed tablet formulation. 
MATERIAL AND METHOD 
Standards of Escitalopram Oxalate and Clonazepam and 
marketed formulations were received as a gift sample from 
Consern Pharma Pvt. Ltd., Sahnewal, Punjab, India. All the 
chemical, solvents and reagents were HPLC and analytical 
grade procured from Merck chemicals, Mumbai, India. Water 
purified via milli-Q 0.45 µ Millipore nylon filter. The 
marketed formulation (ESTax Plus) used for analysis was 
procured from Consern Pharma Pvt. Ltd., Sahnewal, Punjab, 
India. 
Instrumentation and chromatographic conditions: 
Analysis was performed on a Shimadzu HPLC (LC-2010) 
equipped with Prominence LC-Gradient quaternary pump 
(LC-20AD), auto sampler, online degasser,  sampler cooler 
and a SPD-20A prominence PDA  detector. Operation data 
acquisition and analysis were performed by using LC 
solution software. The analytical column C₁₈ column 
(250mm×4.6mm, 5µ) was used for separation. The isocratic 
elution was done with mobile phase of acetonitrile; 
methanol; and 0.05M potassium dihydrogen orthophosphate 
buffer (pH 4 adjusted by orthophosphoric acid) with an 
isocratic ratio of 40:20:40 v/v. Detection was performed by 
using PDA detector at 210 nm.  The flow rate of 1.0 ml min-1 
and created a back pressure of approx. 1039 psi. The buffer 
for mobile phase was prepared by dissolving 2.72 Potassium 
di-hydrogen orthophosphate in 400 ml of water and the pH 
was adjusted to 4  (±0.1) with orthophosphoric acid. Mobile 
phase was filtered through 0.45µ Millipore nylon filter under 
vacuum and ultrasonicated for 10 minutes prior use. The 
column was maintained at 350C temperature, detection was 
carried out using PDA detector at 210 nm and injection 
volume of 20 µl was used for analysis. 
 
Standard solutions and calibration graphs for 
standardization: 
For Stock standard solutions, 100 mg EST and 50 mg CZP 
working standard were separately weighed and transferred 
into 100 ml volumetric flasks respectively. Further, 60 ml of 
mobile phase was added in both volumetric flasks and 
sonicated for 5 minutes and the volume was made with 
mobile phase. Aliquots of standard sub-stock solutions (1ml) 
of EST and CZP were pipette out accurately in 25 ml 
volumetric flask and standard concentration of 40µg/ml and 
20µg/ml were prepared respectively using mobile phase. 
Sample preparation: 
Sample was prepared by weighing accurately 20 tablets of 
combination of EST & CZP in pastel mortar and crushed. 
Weigh accurately sample powder about equivalent to 1/20 
mg of CZP/EST and transfer them to 50ml of volumetric 
flask.  The samples were sonicated for 10 minutes with 5ml 
of water and then add 30 ml of mobile phase and shake to 
dissolve and make volume with Mobile Phase. The above 
sample solutions were filtered through 0.45µ Millipore nylon 
filter paper and used for estimation. 
For Escitalopram: Dilute 1ml from filtered solution to 10ml 
volumetric flask with mobile phase. 
Procedure: Measure area of both standard and sample and 
calculate the result by comparison. Each mg of Escitalopram 
oxalate eq. to 0.782751 mg of Escitalopram. 
Method validation: 
System Suitability Test: 
The system suitability test was conducted to calculate the 
accuracy of the system for the analysis, using six replicate 
injection of a reference solution of EST and CZP. The 
parameters measured were number of theoretical plates, 
retention time, peak area and tailing factor.  
Specificity: 
Specificity is the ability of the method to estimate the 
response of the analyte in the presence of its degradation 
products and potential impurities. The quantity of drugs was 
determined by taking chromatograms by using appropriate 
dilutions16-24. 
Linearity and range: 
Calibration curves were prepared by plotting concentrations 
versus peak area of EST and CZP. It was verified from 80% to 
120% of standards concentration using five calibration 
levels of 80%, 90%, 100%, 110 %, and 120%, (i.e. 
32,36,40,44 and 48 μg/ml for EST and 16,18,20,22 and 24 
μg/ml for CZP). For evaluation of data, method of linear 
regression was used16-24. 
Precision: 
Three replicates of standard solution using with different 
concentrations were used for Precision analysis of the 
analytical method. It was demonstrated by intermediate 
precision (interday precision) and repeatability (intraday 
precision) of the solutions16-24. 
Accuracy: 
It is measure of closeness of experimental values to the true 
value. The previous analyzed samples of EST/CZP 
(10mg/0.5mg) were spiked with extra 50%, 100% and 
150% of the standard EST/CZP, and the proposed method 
was used for re-analysis of mixtures. The experiment was 
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conducted in triplicate. RSD (%) and standard error mean 
(%) were calculated for each concentration. The recovery of 
the drug was ensured at different levels in the 
formulations23. 
Limit of detection (LOD) and Limit of Quantitation 
(LOQ): 
The limit of detection (LOD) and limit of quantification (LOQ) 
were used to describe the smallest concentration of an 
analyte that can be reliably measured by an analytical 
procedure as per ICH guidelines. By using the visual 
evaluation method, LOD was estimated by constant detection 
of the analyte at the minimum level. LOQ’s were expressed as 
the minimum concentration of standard analytes that can be 
reproducibly calculated with acceptable precision and 
accuracy. 
Robustness: 
Robustness of the analytical method referred to its ability to 
remain unaffected by minute, but deliberate changes 
alterations in method parameters16. Robustness was studied 
by analyzing the effect of small and deliberate changes made 
in chromatographic conditions like, temperature of column, 
flow rate, pH and composition of mobile phase25. 
Assay of marketed preparation: 
The prepared sample preparations of EST and CZP were 
tested on HPLC and percentage assay was calculated using 
following formulas. 
 
For EST: 
 Area of sample      Concentration of standard      Average weight of tablet  
             ×                 ×    × 100     = %age assay of EST 
Area of standard     Concentration of sample             Claim of EST 
 
For CZP: 
Area of sample      Concentration of standard      Average weight of tablet  
             ×                 ×    × 100     = %age assay of CZP 
Area of standard     Concentration of sample             Claim of CZP 
 
Forced degradation study: 
Acid Hydrolysis: 
Standards of EST (100mg) and CZP (100mg) were accurately 
weighed and transferred into three sets of 250ml round 
bottom flasks. About 20ml of 2N Hcl was added to all flasks 
and refluxed on heated mantle for 45 min at 80 OC24. 
Alkali Hydrolysis: 
Standards of EST (100mg) and CZP (100mg) were accurately 
weighed and transferred into three 1N NaOH was added to 
all flasks and refluxed on heated mantle for 60 min at 80 
OC24. 
Oxidative Degradation: 
Standards of EST (100mg) and CZP (100mg) were accurately 
weighed and transferred into three sets of 250ml round 
bottom flasks. About 20ml of 6% H2O2 was added to all flasks 
and refluxed on heated mantle for 2 hr. at 80 OC24. 
Thermal Degradation: 
Standard of EST (100mg) and CZP (100mg) was accurately 
weighed and transferred into Petri dish individually and 
spread into thin layer with spatula; this Petri dish was placed 
in the hot air oven for 1 hour at 80OC. Heated drug samples 
of EST (100mg) and CZP (100mg) were taken into 100ml 
volumetric flask and dissolved in diluent. Volume was made 
up to the mark using diluent. 1ml of above sample was 
transferred into 10 ml volumetric flask and diluted up to the 
mark using diluent. It was filtered through 0.45µ Millipore 
nylon filter and filtrate was used for chromatographic 
analysis24. 
Photolytic Degradation: 
Standard of EST (100mg) and CZP (100mg) was accurately 
weighed and transferred into petri dish individually and 
spread into thin layer with spatula; this petri-dish was put 
inside the UV Chamber for 1 hour. UV-exposed drugs 
samples of EST (100mg) and CZP (100mg) were taken into 
100ml volumetric flask, and dissolved in diluent. Volume was 
made up to the mark using diluent. 1ml of above sample was 
taken into 10ml volumetric flask in a few ml of mobile phase 
and sonicated for 10min; this solution was cooled to the 
room temperature and made up the volume up to the mark 
using mobile phase. It was filtered through 0.45µ Millipore 
nylon filter and filtrate was used for chromatographic 
analysis24. 
RESULTS AND DISCUSSION 
Method Optimization: 
In the current study, separation of two analytes was carried 
out using Reversed-phase LC-method. Mobile phase used in 
study consist of mixture of organic solvents i.e. methanol: 
acetonitrile and aqueous buffer. Firstly, the column used was 
a C₁₈ column (250mm×4.6mm, 5µ) as a stationary phase. The 
mobile phase was used as a mixture of acetonitrile; 
methanol; and 0.05M potassium dihydrogen orthophosphate 
buffer with an isocratic ratio of 40:30:30 v/v. Detection was 
performed by using PDA detector at 210 nm.  The flow rate 
was maintained at 0.8 ml/minute which does not show 
enough resolution between analytes. After that, another 
column was used a C₁₈ column (250mm×4.6mm, 5µ) as a 
stationary phase. The mobile phase was used as a mixture of 
acetonitrile; methanol; and 0.05M potassium dihydrogen 
orthophosphate buffer (pH 4 adjusted by orthophosphoric 
acid) with an isocratic ratio of 40:20:40 v/v. Detection was 
performed by using PDA detector at 210 nm. that showed 
adequate resolution between EST and CZP. To optimize the 
chromatographic parameters, the effect on changing the 
composition and pH (range from pH 3-6) of mobile phase 
was studied on the peak asymmetry, theoretical plates, 
retention time, capacity factor (k’) and resolution. The 
selection of the concentration of potassium phosphate buffer 
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(pH 4) and the composition of mobile phase (acetonitrile: 
methanol: buffer :: 40:20:40 v/v) was done on the basis of 
attaining good baseline, adequate separation and sharp 
peaks in a minimum run time. Detection wavelength used at 
210 nm in PDA detector. The injection volume was 20µl as 
well as column temperature was kept at 35oC temperature 
with the run time of 15 minutes. 
 
Method Validation: 
Method validation is the proof needed to ensure that an 
analytical method can produce results which are reliable and 
reproducible and which are fit for the purpose intended. The 
parameters that need to be demonstrated are system 
suitability test, precision, accuracy, specificity, linearity and 
range, limit of detection and limit of quantification and 
robustness as per ICH guidelines. 
 
 
Figure 2: Standard peaks of EST and CPZ 
 
 
Figure 3: Specificity 
 
System Suitability Tests: 
The system suitability test was performed to ensure the 
adequacy, validity and feasibility of the analytical method 
with instrument and also ensures the resolution between 
peaks of different analytes. The system suitability tests was 
applied to a representative chromatogram to confirm the 
various parameters such as peak area, peak asymmetry, 
capacity factor, theoretical plates, resolution, retention time 
and repeatability of the chromatographic system and 
ensures that the equipment, electronics and analytical 
operations for the samples analyzed could be constituted as 
an integral system that can be evaluated as a whole. The RSD 
of peak areas of five consecutive injections was found to less 
than 2%, as 1.28 % for EST and 1.05% for CZP, thus showing 
good repeatability, and excellent chromatographic and 
environmental conditions (Table 1). The resolution between 
the peaks of analytes indicates good separation from each 
other, as resolution found to be greater than 2. Theoretical 
plate number (N) and capacity factor (k´) demonstrated good 
column efficiency (Figure 2). 
Specificity: 
The specificity of a method demonstrates the presence of 
impurities or excipient. Specificity was determined by 
injecting placebo preparation, diluents, standard solution 
and sample preparation. No peak was interfering with 
retention time of analyte peaks (Figure 3). This clearly 
indicates that, excipients don’t interfere with analytes and 
the assay is specific for EST and CZP. 
Linearity and range:  
The linearity of an analytical procedure is its ability (within a 
range) to obtain test results which are directly proportional 
to the concentration (amount) of analyte in the sample.  The 
linearity range is 32 µg/ml to 48 µg/ml for EST with a 
correlation coefficient of 0.9998 and 16 µg/ml to 24 µg/ml 
for CZP with a correlation coefficient of 0.999 (Figure 4). The 
linearity of EST and CZP was found to be in range. 
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(a)                                                                                        (b) 
Figure 4: Linearity plots of (a) EST and (b) CZP 
Precision: 
The precision of an analytical procedure is the spreading of 
results from a replicates sets of measurements. The 
precision, was studied by calculating the RSD value. The 
intermediate precision composed of two parameters: 
intraday (  = 6) and interday (  = 6). The RSD values of 
intraday precision was 0.284 and 1.965 for EST and CZP, 
respectively and of interday precision was 0.168 and 1.442 
for EST and CZP, respectively (Table 2). The RSD value for 
intermediate precision was found to be <2%, which confirms 
that the proposed method is précised. 
 
Table 1: System Suitability Test Parameters 
  
Parameter 
Active Drugs 
EST CZP 
 
Retention time 
Average 4.420 Average 6.535 
Standard Deviation 0.065 Standard Deviation 0.043 
RSD % 0.811 RDS % 0.981 
 
Peak Area 
Average 1578765.89 Average 2589768.33 
Standard Deviation 23243.43 Standard Deviation 49342.19 
RSD % 1.28 RDS % 1.05 
Tailing Factor Average 1.429 Average 1.528 
Standard Deviation 0.016 Standard Deviation 0.098 
Theoretical plates Average 5276.5 Average 4834 
 
Resolution 
Average 8.419 
Standard Deviation 0.045 
  
Table 2: Precision (Intra-day and inter-day study) 
Sample 
(Standard) 
Intra-day study Inter-day study 
EST 
(area) 
CZP 
(area) 
EST 
(area) 
CZP 
(area) 
S1 1576589 2654253 1580143 2653423 
S2 1572342 2533542 1574232 2539353 
S3 1572987 2605423 1576453 2602232 
S4 1583543 2578426 1581668 2586783 
S5 1579934 2576546 1578342 2579245 
S6 1573541 2512548 1578753 2579475 
Mean 1576489.333 2576789.667 1578265.167 2590085.167 
SD 4467.42112 50636.99272 2641.961348 37346.93717 
RSD (%) 0.283377821 1.965119364 0.167396544 1.441919272 
SEM 1823.824289 20672.54794 1078.580494 15246.8839 
 
Table 3:  Accuracy (Recovery study) 
Analyte Concentration 
(µg/ml) 
Amount added Amount 
recovered 
± SD 
Recovery 
(%) 
Average 
recovery 
(%) 
SEM RSD 
(%) (µg/ml) 
EST 40 80 32 31.92 ± 0.055 99.51 99.75 0.031 0.369 
100 40 39.89 ± 0.060 99.45 0.034 0.302 
120 48 48.07 ± 0.061 100.29 0.035 0.244 
CZP 20 80 16 15.28 ± 0.283 98.81 99.00 0.163 0.477 
100 20 19.39 ± 0.330 99.24 0.190 0.417 
120 24 22.97 ± 0.271 98.97 0.156 0.273 
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Accuracy: 
The accuracy of the analytical procedure expresses the 
closeness of mean values for a replicate set of a result to the 
true or accepted value. It can also be termed as trueness. The 
accuracy was assessed by the recovery experiments that 
were performed by the standard addition method. The 
recoveries obtained were 99.75 and 99.00 for EST and CZP, 
respectively (Table 3). Recovery between 80-120% indicates 
that the developed analytical method is accurate for 
determination of pharmaceuticals on combinations. 
Limit of detection (LOD) and Limit of Quantitation 
(LOQ):  
The LOD and LOQ were determined from slops of linear 
regression curves. LOD and LOQ were found to be 0.028 and 
0.079 g/ml for EST and 0.015 and 0.092  g/ml for CZP 
respectively (Table 4). 
Table 4: Results of LOD and LOQ 
Parameter EST (µg/ml) CZP (µg/ml) 
LOD 0.028 0.015 
LOQ 0.079 0.092 
 
Robustness: 
Robustness of analytical method refers to its ability to 
remain unaffected when subjected to small changes in 
method parameters. The method was determined by 
deliberately varying parameter like flow rate and pH of 
mobile phase used for estimation (Table 5). 
 
Table 5: Robustness 
Parameter altered Retention time Peak Area Theoretical Plates 
EST CZP EST CZP EST CZP 
Optimized chromatographic conditions 4.988 6.598 1579832 2567354 5693 4765 
Increased flow rate (1.1mLmin−1) 5.132 6.943 1582354 2616232 5701 4892 
Decreased flow rate (0.9mLmin−1) 4.311 6.054 1569267 2494654 5634 4423 
Increased pH (4.5) 6.213 7.409 1398212 2398761 6231 5987 
Decreased pH (3.5) 4.032 6.121 1425234 2416754 5453 5301 
 
Assay of EST and CZP as tablet in comparison to 
standard: 
The validated method was applied for the simultaneous 
quantification of these drugs in the marketed formulation 
and the percentage assay of EST was found to be 99.01% and 
for CZP found to be 99.57% in comparison to the standard of 
both drugs (Table 6).This clearly justify the assay in between 
90-110% of the label claim. 
 
Table 6: Percentage assay of EST and CZP tablets in comparison to standard 
Drugs Concentration (mg/ml) Peak Area %age Assay 
Standard EST 0.05124(including factor) 1583653 -- 
CZP 0.02016 2560917 -- 
Sample EST 0.04048 1582398 99.01 
CZP 0.0202 2559671 99.57 
 
Table 7: Degradation of EST and CZP at different stress conditions: 
  Stress condition Drugs Peak Area 
% Assay of drug after 
degradation 
% Degradation 
Acidic Degradation 
EST 1058954 66.26 32.75 
CZP 387211 15.03 84.54 
Basic Degradation 
EST 326721 20.44 78.57 
CZP 274904 12.74 86.83 
Oxidative  Degradation 
EST 973361 60.76 38.25 
CZP 2553810 99.34 0.23 
Thermal Degradation 
EST 1579226 98.81 0.20 
CZP 2475282 96.51 3.01 
Photolytic Degradation 
EST 1542957 96.54 2.47 
CZP 2668810 99.19 0.38 
 
Forced degradation study (Stability study): 
Forced degradation study plays a key role in development of 
stability indicating method. This study justified useful 
information about the degradation pathway of drug 
substances and drug products that could be form during 
storage. It was concluded by performing stress testing that 
the method was specific for EST and CZP. Both drugs were 
observed to be highly unstable for acidic, basic conditions 
while CZP is stable in oxidative stress conditions in 
comparison to EST, which is still unstable as per current 
study. So, under these conditions, we should be very careful 
during analysis. Hence, special storage conditions should be 
provided for the dosage form. The chromatograms of 
individual drugs as well as in combination after force 
degradation study under various stress conditions are 
shown in Figures 5-9. The percentage assay and percentage 
degradation of both EST and CZP observed for current 
degradation study is mentioned in Table 7 in comparison to 
assay values of EST and CZP without degradation (Table 6). 
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(a)                                                                                   (b) 
 
 
(c) 
Figure 5: Acidic degradation of (a) EST (b) CZP (c) EST & CZP tablets 
 
                    
(a)                                                                                                    (b) 
 
 
(c) 
Figure 6: Basic degradation of (a) EST (b) CZP (c) EST & CZP tablets 
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(a)                                                                                                (b) 
 
 
(c) 
Figure 7: Oxidative degradation of (a) EST (b) CZP (c) EST & CZP tablets 
           
(a)                                                                       (b) 
        
(c) 
Figure 8: Thermal degradation of (a) EST (b) CZP (c) EST & CZP tablets. 
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(a)                                                                                   (b) 
 
(c) 
Figure 9: Photolytic degradation of (a) EST (b) CZP (c) EST & CZP tablets 
 
CONCLUSION  
A validated stability indicating Reverse phase HPLC method 
has been developed for estimation and quantification of EST 
and CZP as tablet dosage form in combination as per ICH 
guidelines. The mobile phase is simple to prepare and 
economical. The validated results showed that this method 
was specific, sensitive, linear, precise, accurate and robust. It 
can be concluded that this newly developed RP-HPLC 
method can be successfully applied for routine analysis for 
the estimation of combination of EST and CZP in tablet as 
well as bulk dosage form in pharmaceutical industry. 
Degradation studies justified the method specificity for its 
intended application. Therefore, the proposed method can be 
used for routine analysis of two drugs in their combined 
pharmaceutical dosage form. 
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